After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Moderna Inc is $16.16B. A total of 5.29 million shares were traded on the day, compared to an average of 7.53M shares.
In the most recent transaction, Klinger Shannon Thyme sold 529 shares of MRNA for 44.68 per share on Dec 09 ’24. After the transaction, the Chief Legal Officer now owns 20,446 company shares. In a previous transaction on Dec 09 ’24, Klinger Shannon Thyme bought 529 shares at 44.68 per share.
Among the insiders who sold shares, Klinger Shannon Thyme disposed of 112 shares on Dec 03 ’24 at a per-share price of $43.30. This resulted in the Chief Legal Officer holding 19,837 shares of MRNA after the transaction. In another insider transaction, Hoge Stephen sold 314 shares at $43.30 per share on Dec 03 ’24. Company shares held by the President now total 1,443,904.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, MRNA has a high of $170.47 and a low of $35.80.
As of this writing, MRNA has an earnings estimate of -$2.57 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$1.85 per share and a lower estimate of -$3.34.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $30.98, while its Total Shareholder’s Equity was $14.14B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 3.12.
